[Sulfonylurea and alpha-glucosidase inhibitor].
Iijima
Toshihiko
T
Department of Life and Medicine, Urayasu Hospital of Juntendo University School of Medicine.
D050260:Carbohydrate Metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D007294:Inositol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D013453:Sulfonylurea Compounds / Q000008:administration & dosage* / Q000494:pharmacology
D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D007294:Inositol; C102817:voglibose